nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.12.2012 | Preclinical study

Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer

verfasst von: Anoek H. J. Verschuur-Maes, Peter C. de Bruin, Paul J. van Diest

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Promoter hypermethylation of several tumour suppressor genes often occurs during breast carcinogenesis, but little is known about epigenetic silencing in the possible precursor columnar cell lesion (CCL). Promoter hypermethylation of 50 different tumour suppressor genes was assessed in normal breast tissue (N = 10), CCL (N = 15), ductal carcinoma in situ (DCIS) grade I originating in CCL (N = 5) and paired CCL (N = 15) with DCIS (N = 7) and/or invasive carcinoma (N = 14) by Methylation-specific multiplex ligation-dependent probe amplification. Increasing mean cumulative methylation levels were found from normal breast tissue to CCL to DCIS and invasive carcinoma (P < 0.001) with similar methylation levels in DCIS and invasive carcinoma. Methylation levels and frequencies (in the overall analysis and analysis of only the synchronous lesions) were the highest for RASSF1, CCND2, ID4, SCGB3A1 and CDH13. The methylation levels of ID4, CCND2, and CDH13 increased significantly from normal breast tissue to CCL and to DCIS/invasive carcinoma. RASSF1, SCGB3A1 and SFRP5 had significant higher methylation levels in CCL compared to normal breast tissue, but showed no significant differences between CCL, DCIS and invasive carcinoma. Also, no difference was found between CCLs with and without atypia, or CCLs with or without synchronous cancer. In conclusion, promoter hypermethylation for several established tumour suppressor genes is already present in CCLs, underlining that promoter hypermethylation is an early event in breast carcinogenesis. Atypia in CCL or the presence of synchronous more advanced lesions does not seem to be accompanied by higher methylation levels.

Allred DC, Mohsin SK, Fuqua SA (2001) Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 8:47–61PubMedCrossRef

Lee S, Medina D, Tsimelzon A, Mohsin SK, Mao S, Wu Y, Allred DC (2007) Alterations of gene expression in the development of early hyperplastic precursors of breast cancer. Am J Pathol 171:252–262PubMedCrossRef

Simpson PT, Gale T, Reis-Filho JS, Jones C, Parry S, Sloane JP, Hanby A, Pinder SE, Lee AH, Humphreys S, Ellis IO, Lakhani SR (2005) Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. Am J Surg Pathol 29:734–746PubMedCrossRef

Sinn HP (2009) Breast cancer precursors: lessons learned from molecular genetics. J Mol Med 87:113–115PubMedCrossRef

Schnitt SJ, Vincent-Salomon A (2003) Columnar cell lesions of the breast. Adv Anat Pathol 10:113–124PubMedCrossRef

Tavassoli FA, Devilee P (2003) WHO classification tumours of the breast and female genital organs. IARC, Lyon

Feeley L, Quinn CM (2008) Columnar cell lesions of the breast. Histopathology 52:11–19PubMedCrossRef

Verschuur-Maes AHJ, Van Deurzen CHM, Monninkhof EM, van Diest PJ (2011) Columnar cell lesions on breast needle biopsies: is surgical excision necessary? A systematic review. Ann Surg 255:259–265CrossRef

Aulmann S, Elsawaf Z, Penzel R, Schirmacher P, Sinn HP (2009) Invasive tubular carcinoma of the breast frequently is clonally related to flat epithelial atypia and low-grade ductal carcinoma in situ. Am J Surg Pathol 33:1646–1653PubMedCrossRef

10.

Dabbs DJ, Carter G, Fudge M, Peng Y, Swalsky P, Finkelstein S (2006) Molecular alterations in columnar cell lesions of the breast. Mod Pathol 19:344–349PubMedCrossRef

11.

Moinfar F, Man YG, Bratthauer GL, Ratschek M, Tavassoli FA (2000) Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type (“clinging ductal carcinoma in situ”): a simulator of normal mammary epithelium. Cancer 88:2072–2081PubMedCrossRef

12.

Buyru N, Altinisik J, Ozdemir F, Demokan S, Dalay N (2009) Methylation profiles in breast cancer. Cancer Invest 27:307–312PubMedCrossRef

13.

Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG (2000) Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92:564–569PubMedCrossRef

14.

Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683–692PubMedCrossRef

15.

Jovanovic J, Ronneberg JA, Tost J, Kristensen V (2010) The epigenetics of breast cancer. Mol Oncol 4:242–254PubMedCrossRef

16.

Marzese DM, Gago FE, Vargas-Roig LM, Roque M (2010) Simultaneous analysis of the methylation profile of 26 cancer related regions in invasive breast carcinomas by MS-MLPA and drMS-MLPA. Mol Cell Probes 24:271–280PubMedCrossRef

17.

Widschwendter M, Jones PA (2002) DNA methylation and breast carcinogenesis. Oncogene 21:5462–5482PubMedCrossRef

18.

Hoque MO, Prencipe M, Poeta ML, Barbano R, Valori VM, Copetti M, Gallo AP, Brait M, Maiello E, Apicella A, Rossiello R, Zito F, Stefania T, Paradiso A, Carella M, Dallapiccola B, Murgo R, Carosi I, Bisceglia M, Fazio VM, Sidransky D, Parrella P (2009) Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression. Cancer Epidemiol Biomarkers Prev 18:2694–2700PubMedCrossRef

19.

Liu T, Niu Y, Feng Y, Niu R, Yu Y, Lv A, Yang Y (2008) Methylation of CpG islands of p16(INK4a) and cyclinD1 overexpression associated with progression of intraductal proliferative lesions of the breast. Hum Pathol 39:1637–1646PubMedCrossRef

20.

Park SY, Kwon HJ, Lee HE, Ryu HS, Kim SW, Kim JH, Kim IA, Jung N, Cho NY, Kang GH (2011) Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch 458:73–84PubMedCrossRef

21.

van Diest PJ (2002) No consent should be needed for using leftover body material for scientific purposes. BMJ 325:648–651PubMedCrossRef

22.

Bol GM, Suijkerbuijk KP, Bart J, Vooijs M, van der Wall E, van Diest PJ (2010) Methylation profiles of hereditary and sporadic ovarian cancer. Histopathology 57:363–370PubMedCrossRef

23.

Seeber LM, Zweemer RP, Marchionni L, Massuger LF, Smit VT, van Baal WM, Verheijen RH, van Diest PJ (2010) Methylation profiles of endometrioid and serous endometrial cancers. Endocr Relat Cancer 17:663–673PubMedCrossRef

24.

Suijkerbuijk KP, Pan X, Van der Wall E, van Diest PJ, Vooijs M (2010) Comparison of different promoter methylation assays in breast cancer. Anal Cell Pathol (Amst) 33:133–141

25.

van Diest PJ, Suijkerbuijk KP, Koop EA, de Weger RA, Van der Wall E (2010) Low levels of BNIP3 promoter hypermethylation in invasive breast cancer. Anal Cell Pathol (Amst) 33:175–176

26.

Gylling A, Abdel-Rahman WM, Juhola M, Nuorva K, Hautala E, Jarvinen HJ, Mecklin JP, Aarnio M, Peltomaki P (2007) Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study. Gut 56:926–933PubMedCrossRef

27.

Joensuu EI, Abdel-Rahman WM, Ollikainen M, Ruosaari S, Knuutila S, Peltomaki P (2008) Epigenetic signatures of familial cancer are characteristic of tumor type and family category. Cancer Res 68:4597–4605PubMedCrossRef

28.

Suijkerbuijk KP, Fackler MJ, Sukumar S, van Gils CH, van Laar T, Van der Wall E, Vooijs M, van Diest PJ (2008) Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer. Ann Oncol 19:1870–1874PubMedCrossRef

29.

30.

O’Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC (1998) Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 90:697–703PubMedCrossRef

31.

32.

Qi L, Bart J, Tan LP, Platteel I, Sluis T, Huitema S, Harms G, Fu L, Hollema H, Berg A (2009) Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer 9:163PubMedCrossRef

33.

Ellsworth RE, Ellsworth DL, Weyandt JD, Fantacone-Campbell JL, Deyarmin B, Hooke JA, Shriver CD (2010) Chromosomal alterations in pure nonneoplastic breast lesions: implications for breast cancer progression. Ann Surg Oncol 17:1688–1694PubMedCrossRef

34.

Subramaniam MM, Chan JY, Omar MF, Ito K, Ito Y, Yeoh KG, Salto-Tellez M, Putti TC (2010) Lack of RUNX3 inactivation in columnar cell lesions of breast. Histopathology 57:555–563PubMedCrossRef

35.

Fackler MJ, McVeigh M, Evron E, Garrett E, Mehrotra J, Polyak K, Sukumar S, Argani P (2003) DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 107:970–975PubMedCrossRef

36.

Moelans CB, de Weger RA, Monsuur HN, Maes AH, van Diest PJ (2010) Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. Anal Cell Pathol (Amst) 33:165–173

37.

Muggerud AA, Ronneberg JA, Warnberg F, Botling J, Busato F, Jovanovic J, Solvang H, Bukholm I, Borresen-Dale AL, Kristensen VN, Sorlie T, Tost J (2010) Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res 12:R3PubMedCrossRef

38.

Bertolo C, Guerrero D, Vicente F, Cordoba A, Esteller M, Ropero S, Guillen-Grima F, Martinez-Penuela JM, Lera JM (2008) Differences and molecular immunohistochemical parameters in the subtypes of infiltrating ductal breast cancer. Am J Clin Pathol 130:414–424PubMedCrossRef

39.

Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M, Minna JD (2001) Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93:691–699PubMedCrossRef

40.

Chen CM, Chen HL, Hsiau TH, Hsiau AH, Shi H, Brock GJ, Wei SH, Caldwell CW, Yan PS, Huang TH (2003) Methylation target array for rapid analysis of CpG island hypermethylation in multiple tissue genomes. Am J Pathol 163:37–45PubMedCrossRef

41.

Feng W, Orlandi R, Zhao N, Carcangiu ML, Tagliabue E, Xu J, Bast RC Jr, Yu Y (2010) Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. BMC Cancer 10:378PubMedCrossRef

42.

Honorio S, Agathanggelou A, Schuermann M, Pankow W, Viacava P, Maher ER, Latif F (2003) Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene 22:147–150PubMedCrossRef

43.

Lee JS, Fackler MJ, Teo WW, Lee JH, Choi C, Park MH, Yoon JH, Zhang Z, Argani P, Sukumar S (2008) Quantitative promoter hypermethylation profiles of ductal carcinoma in situ in North American and Korean women: potential applications for diagnosis. Cancer Biol Ther 7:1398–1406PubMed

44.

Pasquali L, Bedeir A, Ringquist S, Styche A, Bhargava R, Trucco G (2007) Quantification of CpG island methylation in progressive breast lesions from normal to invasive carcinoma. Cancer Lett 257:136–144PubMedCrossRef

45.

Shinozaki M, Hoon DS, Giuliano AE, Hansen NM, Wang HJ, Turner R, Taback B (2005) Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res 11:2156–2162PubMedCrossRef

46.

Noetzel E, Veeck J, Niederacher D, Galm O, Horn F, Hartmann A, Knuchel R, Dahl E (2008) Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer. BMC Cancer 8:154PubMedCrossRef

47.

Umetani N, Mori T, Koyanagi K, Shinozaki M, Kim J, Giuliano AE, Hoon DS (2005) Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. Oncogene 24:4721–4727PubMedCrossRef

48.

Evron E, Umbricht CB, Korz D, Raman V, Loeb DM, Niranjan B, Buluwela L, Weitzman SA, Marks J, Sukumar S (2001) Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res 61:2782–2787PubMed

49.

Li S, Rong M, Iacopetta B (2006) DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett 237:272–280PubMedCrossRef

50.

Parrella P, Poeta ML, Gallo AP, Prencipe M, Scintu M, Apicella A, Rossiello R, Liguoro G, Seripa D, Gravina C, Rabitti C, Rinaldi M, Nicol T, Tommasi S, Paradiso A, Schittulli F, Altomare V, Fazio VM (2004) Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res 10:5349–5354PubMedCrossRef

51.

Shigematsu H, Suzuki M, Takahashi T, Miyajima K, Toyooka S, Shivapurkar N, Tomlinson GE, Mastrangelo D, Pass HI, Brambilla E, Sathyanarayana UG, Czerniak B, Fujisawa T, Shimizu N, Gazdar AF (2005) Aberrant methylation of HIN-1 (high in normal-1) is a frequent event in many human malignancies. Int J Cancer 113:600–604PubMedCrossRef

52.

Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, Gilcrease M, Minna JD, Gazdar AF (2001) Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res 61:4556–4560PubMed

53.

Suzuki H, Toyota M, Carraway H, Gabrielson E, Ohmura T, Fujikane T, Nishikawa N, Sogabe Y, Nojima M, Sonoda T, Mori M, Hirata K, Imai K, Shinomura Y, Baylin SB, Tokino T (2008) Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer 98:1147–1156PubMedCrossRef

54.

Veeck J, Geisler C, Noetzel E, Alkaya S, Hartmann A, Knuchel R, Dahl E (2008) Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis. Carcinogenesis 29:991–998PubMedCrossRef

Titel: Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer
verfasst von: Anoek H. J. Verschuur-Maes
Peter C. de Bruin
Paul J. van Diest
Publikationsdatum: 01.12.2012
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-012-2301-4

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?

Collaborative modeling of the impact of obesity on race-specific breast cancer incidence and mortality

Alcohol consumption suppresses mammary tumor metastasis in a syngeneic tumor transplantation model

Erratum to: Women’s features and inter-/intra-rater agreement on mammographic density assessment in full-field digital mammograms (DDM-SPAIN)

Association of large noncoding RNA HOTAIR expression and its downstream intergenic CpG island methylation with survival in breast cancer

Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie